Treatment of allograft vasculopathy in heart transplantation

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 17, 2006, Pages 2369-2383

  Segovia, Javier ^a   Gómez Bueno, Manuel ^a   Alonso Pulpón, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cardiac allograft vasculopathy

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; GANCICLOVIR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRATE; PREDNISONE; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; STEROID; TSUKUBAENOLIDE; VALGANCICLOVIR; VASODILATOR AGENT; VITAMIN;

ADOPTIVE IMMUNOTHERAPY; ANEMIA; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE EXACERBATION; DISEASE SEVERITY; DNA MICROARRAY; DRUG COST; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GENE THERAPY; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; KIDNEY FAILURE; MOUTH ULCER; NONHUMAN; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PNEUMONIA; PREVALENCE; RETRANSPLANTATION; REVIEW; SCORING SYSTEM; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION; WOUND HEALING IMPAIRMENT;

CORONARY ARTERIOSCLEROSIS; EXPERT TESTIMONY; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION, HOMOLOGOUS; VASODILATOR AGENTS;

EID: 33751579089     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.17.2369     Document Type: Review

References (154)

1. TAYLOR DO, EDWARDS LB, BOUCEK MM et al.: The Registry of the International Society for Heart and Lung Transplantation. Twenty-second official adult heart transplant report-2005. J. Heart Lung Transplant. (2005) 24:945-955.
2. BENZA RL, TALLAJ J: Cardiac allograft vasculopathy (Chronic rejection). In: Heart Transplantation (Chapter 17). Kirklin JK, Young JB, McGiffin DC (Eds). Churchill Livingstone, New York, NY, USA (2002):615-665.
3. ARANDA JM, HILL J: Cardiac transplant vasculopathy. Chest (2000) 118:1792-1800.
4. WEIS M, VON SCHEIDT W: Coronary artery disease in the transplanted heart. Annu. Rev. Med. (2000) 51:81-100.
5. TAYLOR DO, EDWARDS LB, BOUCECK MM et al.: Registry of the International Society of Heart and Lung Transplantation: twenty third official adult heart transplantation report - 2006. J. Heart Lung Transplant. (2006) 25:869-879.
6. SYEDA B, ROEDLER S, SCHUKRO C et al.: Transplant coronary artery disease: incidence, progression, and interventional revascularization. Int. J. Cardiol. (2005) 104:269-274.
7. SEGOVIA J, ALONSO-PULPÓN L, JIMÉNEZ-MAZUECOS J et al.: Intravascular ultrasound findings 10 years after heart transplantation. J. Heart Lung Transplant. (2004) 23(Suppl. 2):s72.
8. COSTANZO MR, NAFTEL DC, PRITZKER MR et al.: Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of pre-operative donor and recipient risk actors. J. Heart Lung Transplant. (1998) 17:744-753.
9. MULLINS PA, CARY N, SHARPLES L et al.: Coronary occlusive disease and late graft failure after heart transplantation. Br. Heart J. (1992) 68:260-265.
10. CANTIN B, GAO SZ, KWOK BWK et al.: Mild cardiac allograft coronary disease does not change the prognosis of patients after heart transplantation. J. Heart Lung Transplant. (2002) 21:88 Abstract.
11. HIEMANN NE, MEYER R, WELLNHOFER E et al.: Correlation of angiographic and immunohistochemical findings in graft vessel disease after heart transplantation. Transplant Proc. (2001) 33:1586-1590.
12. AZIZ T, BURGESS M, RAHMAN AN et al.: Cardiac transplantation for cardiomyopathy and ischemic heart disease: differences in outcome up to 10 years. J. Heart Lung Transplant. (2001) 20:525-533.
13. HATHOUT E, BEESON WL, KUHN M et al.: Cardiac allograft vasculopathy in pediatric heart transplant recipients. Transpl. Int. (2006) 19:184-189.
14. GALLO P, AGOZZINO L, ANGELINI A et al.: Causes of late failure after heart transplantation: a ten-year survey: J. Heart Lung Transplant. (1997) 16:1113-1121.
15. KEOGH AM, VALANTINE HA, HUNT SA et al.: Impact of proximal or midvessel discrete coronary artery stenosis on survival after heart transplantation. J. Heart Lung Transplant. (1992) 11:892-901.
16. CANTIN B, GAO SZ, KWOK BWK et al.: Prognosis of patients with significant angiographically diagnosed cardiac allograft coronary disease. J. Heart Lung Transplant. (2002) 21:96 Abstract.
17. KIRKLIN JK, NAFTEL DC, BOURGE RC et al.: Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J. Thor. Cardiovasc. Surg. (2003) 125:881-890.
18. ALMENAR L: Registro Español de Traaplante Cardiaco. XVI informe oficial (1984-2004). Rev. Esp. Cardiol. (2005) 58:1310-1317.
19. HAUPTMAN PJ, MEHRA MR: It is time to stop ignoring malignancy in heart transplantation: a call to arms. J. Heart Lung Transplant. (2005) 24:1111-1113.
20. SEGOVIA J: Update on cardiac allograft vasculopathy. Curr. Opin. Organ Transpl. (2002) 7:240-251.
21. AVERY RK: Cardiac-allograft vasculopathy. N. Engl. J. Med. (2003) 349:829-830.
22. VALANTINE H: Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. (2004) 23(Suppl.):S187-S193.
23. SEGOVIA J, ALONSO-PULPÓN L, JIMÉNEZ-MAZUECOS J et al.: Influence of tobacco addition in the outcome of heart transplant recipients. J. Heart Lung Transpl. (2006) 25(Suppl.):45-46.
24. POGGIO ED, RODDY M, RILEY J et al.: Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy. J. Heart Lung Transpl. (2005) 24:1606-1613.
25. STOICA SC, GODDARD M, LARGE SR: The endothelium in clinical cardiac transplantation. Ann. Thorac. Surg. (2002) 73:1002-1008.
26. PINNEY SP, MANCINI D: Cardiac allograft vasculopathy: advances in understanding its pathology: prevention and treatment. Curr. Opin. Cardiol. (2004) 19:170-176.
27. RAMZY D, RAO V, BRAHM J, MIRIUKA S, DELGADO D, ROSS HJ: Cardiac allograft vasculopathy: a review. Can. J. Surg. (2005) 48:319-327.
28. KASS M, HADDAD H: Cardiac allograft vasculopathy: pathology, prevention and treatment. Curr. Opin. Cardiol. (2006) 21:132-137.
29. CAFORIO AL, TONA F, FORTINA AB et al.: Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate analysis and role of immunosuppression. Am. J. Transplant. (2004) 4:962-970.
30. LEE RS, YAMADA K, HOUSER SL et al.: Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant Proc. (2001) 33:308-310.
31. HOLLENBERG SM, KLEIN LW, PARRILLO JE et al.: Coronary endothelial dysfunction after graft transplantation predicts allograft vasculopathy and cardiac death. Circulation (2001) 104:3091-3096.
32. LABARRERE CA, NELSON DR, PARK JW: Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr. Opin. Cardiol. (2001) 16:110-117.
33. VEJLSTRUP NG, ANDERSEN CB, BOESGAARD S et al.: Temporal changes in myocardial endothelial nitric oxide synthase expression following human heart transplantation. J. Heart Lung Transplant. (2002) 21:211-216.
34. GALLEGO-PAGE JC, SEGOVIA J, ALONSO-PULPÓN L et al.: Re-innervation after heart transplantation: a multidisciplinary study. J. Heart Lung Transplant. (2004) 23:674-682.
35. SMART FW, BALLANTYNE CM, COCANOUGHER B et al.: Insensitivity of noninvaslve tests to detect coronary artery vasculopathy after heart transplantation. Am. J. Cardiol. (1991) 67:243-247.
36. LEGARE JF, HADDAD H, BARNES D et al.: Myocardial scintigraphy correlates poorly with coronary angiography in the screening of cardiac arteriosclerosis. Can. J. Cardiol. (2001) 17:866-872.
37. SPES CH, KLAUSS V, MUDRA H et al.: Diagnostic and prognostic value of serial dobutamine stress echocardiography for non-invasive assessment of cardiac allograft vasculopathy: a comparison with coronary angiography and intravascular ultrasound. Circulation (1999) 100:509-515.
38. KNOLLMANN FD, BOCKSCH W, SPIEGELSBERGERS et al.: Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation (2000) 101:2078-2082.
39. CARLSEN J, TOFT JC, MORTENSEN SA et al.: Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients. J. Heart Lung Transplant. (2000) 19:873-878.
40. HERSHBERGER RE, NI H, TOY W et al.: Distribution and declines in cardiac allograft radionuclide left ventricular ejection fractions in relation to late mortality. J. Heart Lung Transplant. (2001) 20:417-424.
41. ALLEN-AUERBACH M, SCHÖDER H, JOHNSON J et al.: Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J. Heart Lung Transplant. (1999) 18:211-219.
42. MUEHLING OM,, PANSE P, JEROSCH-HEROLD M, WILSON BV, WILSON RF, WILKE NM, MILLER LW: Cardiac magnetic resonance perfusion imaging identifies transplant arteriopathy by a reduced endomyocardial resting perfusion. J. Heart Lung Transplant. (2005) 24:1122-1123.
43. ROMEO G, HOUYEL L, ANGEL C-Y, BRENOT P, RENOU J-Y, PAUL J-F: Coronary stenosis detection by 16-slice computed tomography in heart transplant recipients. J. Am. Coll. Cardiol. (2005) 45:1826-1831.
44. KITAGAWA-SAKAKIDA S, FUKUSHIMA N, SAWA Y, HORIGUCHI K, DOI T, SHIKAKURA R, MATSUDA H: Microarray-based gene expression profiling of retransplanted rat cardiac allografts that develop cardiac allograft vasculopathy. J. Heart Lung Transpl. (2005) 24:2068-2074.
45. DENG MC, EISEN HJ, MEHRA MR et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. (2006) 6:150-160.
46. MEHRA MR, UBER PA, POTLURI S, VENTURA HO, SCOTT RL, PARK MH: Usefulness of an elevated B-type natriurético peptide to predict allograft fulure, cardiac allograft vasculopathy, and survival after heart transplantation. Am. J. Cardiol. (2004) 94:454-458.
47. JOHNSON DE, ALDERMAN EL, SCHROEDER JS et al.: Transplant coronary artery disease: histopathologic correlations with angiographic morphology. J. Am. Coll. Cardiol. (1991) 17:449-457.
48. YEUNG AC, DAVIS SF, HAUPTMAN PJ et al.: Multicentre intravascular ultrasound study group: Incidence and progression of transplant coronary disease over 1 year: results of a multicentre trial with the use of intravascular ultrasound. J. Heart Lung Transplant. (1995) 14:S215-S220.
49. KAPADIA SR, NISSEN SE, TUZCU EM: Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr. Opin. Cardiol. (1999) 14:140-150.
50. MURAT TUZCU E, KAPADIA SR, TUTAR E et al.: High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation (2001) 103:2705-2710.
51. BROCK MV, SALAZAR JD, CAMERON DE et al.: The changing profile of the cardiac donor. J. Heart Lung Transplant. (2001) 20:1005-1009.
52. KAPADIA SR, NISSEN SE, ZIADA KM et al.: Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation (1998) 98:2672-2678.
53. BOTAS J, PINTO FJ, CHENZBRAUN A et al.: Influence of preexistent donor coronary artery disease on progression of transplant vasculopathy: an intravascular ultrasound study. Circulation (1995) 92:1126-1132.
54. TSUTSUI H, SCHOENHAGEN P, KLINGENSMITH JD et al.: Regression ofa donor atheroma after heart transplantation: serial observations with intravascular ultrasound. Circulation (2001) 104:2874.
55. YEUNG AC, DAVIS SF, HAUPTMAN PJ et al.: Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J. Heart Lung Transplant. (1995) 14:S215-S120.
56. RICKENBACHER PR, PINTO FJ, CHENZBRAUN A et al.: Incidence and severity of transplant coronary arterry disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J. Am. Coll. Cardiol. (1995) 25:171-177.
57. KLAUSS V, MUDRA H, ÜBERFUHR P et al.: Intraindividual variability of cardiac allograft vasculopathy as assessed by intravascular ultrasound. Am. J. Cardiol. (1995) 76:463-466.
58. WONG CK, YEUNG AC: The topography of intimal thickening and associated remodeling pattern of early transplant coronary disease: influence of pre-existent coronary atherosclerosis. J. Heart Lung Transplant. (2001) 20:858-864.
59. KAPADIA SR, ZIADA KM, L'ALLIER PL et al.: Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J. Heart Lung Transplant. (2000) 19:167-172.
60. PETHIG K, KOFIDIS T, HEUBLEIN B et al.: Impact of vascular branching sites on focal progression of allograft vasculopathy in transplanted hearts. Atherosclerosis (2001) 158:155-160.
61. TSUTSUI H, ZIADA KM, SCHOENHAGEN P et al.: Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation (2001) 104:653-657.
62. WONG CK, GANZ P, MILLER L et al.: Role of vascular remodeling in the pathogenesis of early transplant coronary disease: a multicenter prospective intravascular ultrasound study. J. Heart Lung Transplant. (2001) 20:385-392.
63. SCHOENHAGEN P, ZIADA KM, VINCE C et al.: Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J. Am. Coll. Cardiol. (2001) 38:297-306.
64. PETHIG K, HEUBLEIN B, MELISS RR et al.: Volumetric remodeling of the proximal left coronary artery: early versus late after heart transplantation. J. Am. Coll. Cardiol. (1999) 34:197-203.
65. ST GOAR FJ, PINTO FJ, ALDERMAN EL et al.: Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of "angiographically silent" intimal thickening. Circulation (1992) 85:979-987.
66. ZACLICZYNSKI M, SWIERAD M, ZACLICZYNSKA H, MARUSZEWSKI M, BUSZMAN P, ZEMBALA M: Usefulness of Stanford scale of intimal hyperplasia assessed by intravascular ultrasound to predict time of onset and severity of cardiac allograft vasculopathy. Transplant Proc. (2005) 37:1343-1345.
67. SEGOVIA J, ALONSO-PULPÓN L, ESCANED J et al.: Prognostic value of a new intravascular ultrasound score in graft vessel disease. J. Heart Lung Transplant. (2001) 20:151 Abstract.
68. GÓMEZ BUENO M, SEGOVIA J, ALONSO-PULPÓN L et al.: Validation of the prognostic value of a new intravascular ultrasound score for the evaluation of graft vessel disease. J. Heart Lung Transpt (2006) 25(Suppl.):99.
69. KOBASHIGAWA JA, TOBIS JM, STARLING RC et al.: Multicenter intravascular ultrasound validation study among heart transplant recipients. J. Am. Coll. Cardiol. (2005) 45:1532-1537.
70. KLAUSS V, ACKERMANN K, HENNEKE K-H et al.: Epicardial intimal thickening in transplant coronary artery disease and resistance response to adenosine: a combined intravascular ultrasound and Doppler study. Circulation (1997) 96(Suppl.):II-159-164.
71. YEUNG AC: Simultaneous evaluation of epicardial and microvascular function in human beings: a technical tour de force. J. Heart Lung Transplant. (1998) 117:495-496.
72. PINTO FJ, ST: GOAR FC, GAO SZ et al.: Immediate and 1-year safety of intracoronary ultrasonic imaging: evaluation with serial quantitative angiography. Circulation (1993) 88:1709-1714.
73. POELZL G, ULLRICH R HUBER A et al.: Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy. Transpl. Int. (2005) 18:313-317.
74. ESCANED J, SEGOVIA J, FLORES A et al.: Assessment of coronary microcirculation in cardiac allografts: a comparison of intracoronary physiology, intravascular ultrasound and histological morphometry. J. Heart Lung Transplant. (2001) 20:204-205. Abstract.
75. YEUNG AC, ANDERSON T, MEREDITH I et al.: Endothelial dysfunction in the development and detection of transplant coronary artery disease. J. Heart Lung Transplant. (1992) 11:S69-S73.
76. WEIS M, WILDHIRT SM, PEHLIVANLI S et al.: Early cytokine activation leads to subsequent endothelial vaaomotor dysfunction after cardiac transplantation. Circulation (1998) 17(Suppl. I):I-319.
77. DAVIS SF, YEUNG AC, MEREDITH IT et al.: Early endothelial dysfunction predicts the development of transplant coronary disease at 1 year post-transplantation. Circulation (1996) 93:457-462.
78. WELLNHOFER E, BOCKSCH W, HIEMANN N et al.: Shear stress and vascular remodeling: study of cardiac allograft coronary artery disease as a model of diffuse atherosclerosis. J. Heart Lung Transplant. (2002) 21:405-416.
79. RODRIGUES ACT, FRIMM CC, BACAL F et al.: Coronary flow reserve impairment predicts cardiac events in heart transplant patients with preserved left ventricular function. Int. J. Cardiol. (2005) 103:201-206.
80. POTLURI SP, MEHRA MR, UBER PA, PARK MH, SCOTT RL, VENTURA HO: Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival after heart transplantation. J. Heart Lung Transplant. (2005) 24:1019-1025.
81. HOLLENBERG SM, TAMBURRO P, KLEIN LW et al.: Discordant epicardial and microvascular endothelial responses in heart transplantation recipients early after transplantation. J. Heart Lung Transplant. (1998) 17:487494.
82. RICHTER M, RICHTER H, SKUPIN M et al.: Do vascular compartments differ in the development of chronic rejection? AT1 blocker candesartan versus ACE blocker enalapril in an experimental heart transplant model. J. Heart Lung Transplant. (2001) 20:1092-1098.
83. SUBHERWAL S, ESPEJO ML, FISHBEIN MC et al.: The decreasing incidence of cardiac allograft rejection and its impact on clinical trials. J. Heart Lung Transplant. (2002) 21:111 Abstract.
84. LUCKRAZ H, CHARMAN SC, WREGHITT T, WALLWORK J, PARAMESHWAR J, LARGE SR: Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J. Heart Lung Transplant. (2003) 22:1023-1027.
85. MEHRA MR, VENTURA HO, CHAMBERS RB et al.: The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J. Heart Lung Transplantation (1997) 16:743-751.
86. KOGLIN J, MUSCHOLL M, PETRAKOPOULOU P et al.: Tacrolimus excels cyclosporine A in prevention of cardiac allograft vasculopathy - a prospective IVUS, angiography and Doppler study. J. Heart Lung Transplant. (2002) 21:68 Abstract.
87. REICHART B, MEISER B, VIGANO M et al.: European Multicenter Tacrolimus (FK506) Heart pilot study: one year results - European Tacrolimus Multicenter Heart Study Group. J. Heart Lung Transplant. (1998) 17:775-781.
88. PHAM SL, KORMOS RL, HATTLER BG et al.: A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate term-results. J. Thorac. Cardiovasc. Surg. (1996) 11:764-772.
89. KLAUSS V, KÖNIG A, SPES C et al.: Cyclosporine versus tacrolimus (FK506) for prevention of cardiac allograft vasculopathy. Am. J. Cardiol. (2000) 85:266-269.
90. EISEN HJ, KOBASHIGAWA J, KEOGH A et al.: Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. (2005) 24:517-525.
91. GAO SK, KWOK BWK, CANTIN B: Does late switch to mycophenolate mofetil affect development of transplant coronary artery disease? J. Heart Lung Transplant. (2002) 21:89 Abstract.
92. COLE OJ, SHEHATA M, RIGG KM et al.: Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc. (1998) 30:2200-2203.
93. DAMBRIN C, KLUPP J, BIRSAN T et al.: Sirolimus (rapamycin) monotherapy prevents graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Circulation (2003) 107:2369-2374.
94. EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N. Engl. J. Med. (2003) 349:847-858.
95. MANCINI D, VIGANO M, ALONSO-PULPÓN L et al.: 24-month results of a multicentre study of Certican for the prevention of allograft rejection and vasculopathy in de novo Herat transplant recipients. Am. J. Transplant. (2003) 3:550.
96. EISEN H, STARLING R, KOBASHIGAWA J: Incidence of MACE and economic burden in de novo heart transplant patients: a comparison of everolimus and azathioprine. J. Heart Lung Transplant. (2006) 25(Suppl.):S59 Abstract.
97. KEOGH A, RICHARDSON M, RUYGROK P et al.: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation (2004) 110:2694-2700.
98. KOEHL GE, ANDRASSY J, GUBA M et al.: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 77:1319-1326.
99. KILO J, LAUFER G, ANTRETTER H: proliferation signal inhibitors: a new substance class in immunosuppression after heart transplantation. Curr. Opin. Organ Transplant. (2005) 10:355-359.
100. GROETZNER J, WAHLERS T: Calcineurin inhibitor-free immunosuppression after heart transplantation: can chronic side effects be avoided? Curr. Opin. Organ Transplant. (2005) 10:360-363.
101. GROETZNER J, MEISER B, LANDWEHR P et al.: Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for cardiac transplant recipients with chronic renal failure. Transplantation (2004) 77:568-574.
102. MEISER B, REICHART B, ADAMIDIS I et al.: First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am. J. Transplant. (2005) 5:827-831.
103. ANGUITA M, ALONSO-PULPÓN L, ARIZON JM et al.: A comparison of the effectiveness of lovastatin therapy for hipercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic CAD. Am. J. Cardiol. (1994) 74:776-779.
104. KOBASHIGAWA JA, KATZNELSON L, LAKS H et al.: Effects of pravastatin on outcomes after heart transplantation. N. Engl. J. Med. (1995) 333:621-627.
105. WENKE K, MEISER B, THIERY J et al.: Simvastatin initiated early after - 8-year prospective experience. Circulation (2003) 107:93-97.
106. WU AH, BALLANTYNE C, SHORT BC et al.: Statin use and risks of death or fatal rejection in the heart transplant lipid registry. Am. J. Cardiol. (2005) 95:367-372.
107. WEIS M, PEHLIVANLI S, MEISER BM et al.: Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J. Am. Coll. Cardiol. (2001) 38:814-818.
108. SHIMIZU K, AIKAWA M, TAKAYAMA K, LIBBY P, MITCHELL RN: Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft atherosclerosis by statins. Circulation (2003) 108:2113-2120.
109. STAPLETON DD, MEHRA MR, DUMAS D et al.: lipid-lowering therapy and long-term survival in heart transplantation. Am. J. Cardiol. (1997) 80:802-805.
110. PAUL LC: Calcium channel blockers and ACE inhibitors in the prevention of graft vasculopathy. J. Heart Lung Transplant. (2000) 19:409-413.
111. SCHROEDER JS, GAO SZ, ALDERMAN EL et al: A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N. Engl. J. Med. (1993) 328:164-170.
112. MEHRA MR, VENTURA HO, SMART FW, STAPLETON DD: An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blocker on the development of cardiac allograft vasculopathy. Am. J. Cardiol. (1995) 75:853-854.
113. ERINC K, YAMANI MH, STARLING RC et al.: The effect of combined angiotensine-conversing enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J. Heart Lung Transplant. (2005) 24:1033-1038.
114. EL-HAMAMSY I, STEVENS LM, VANHOUTTE PM, PERRAULT LP: Injury of the coronary endothelium at implantation increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J. Heart Lung Transplant. (2005) 24:251-258.
115. PERRAULT LP, NICKNER C, DESJARDINS N et al.: Improved preservation of coronary endothelial function with Celsior compared with blood and crystalloid solutions in heart transplantation. J. Heart Lung Transplant. (2001) 20:549-558.
116. CASTEDO E, SEGOVIA J, ESCUDERO C et al.: Ischemia-reperfusion injury during experimental heart transplantation. Evaluation of trimetazidines cytoprotective effect. Rev. Esp. Cardiol. (2005) 58:941-950.
117. FEDAK PW, RAO V, VERMA S et al.: Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J. Thorac. Cardiovasc. Surg. (2005) 129:407-415.
118. RAMZY D, RAO V, MALLIDI H et al.: Cardiac allograft preservation using donor-shed blood supplemented with L-arginine. J. Heart Lung Transplant. (2005) 24:1665-1672.
119. KUTSCHKA I, PETHIG K, STRÜBER M et al.: Homocysteine-a treatable risk factor for allograft vascular disease after heart transplantation? J. Heart Lung Transplant. (2001) 20:743-746.
120. MINER SES, COLE DEC, EVROVSKI J et al.: Pyridoxine improves endothelial function in cardiac transplant recipients. J. Heart Lung Transplant. (2001) 20:964-969.
121. RAMZY D, RAO V, BRAHM J, MIRIUKA S, DELGADO D, ROSS HJ: Cardiac allograft vasculopathy: a review. Can. J. Surg. (2005) 48:319-327.
122. MURATA S, SUNDELL CL, LIJKWAN MA: Effects oF AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis. Transplantation (2004) 77:1494-1500.
123. CLAUSELL N, MOLOOSI S, SETT S et al.: In-vivo blockade of tumour necrosis factor-α in cholesterol fed rabbits after cardiac transplant inhibits acute coronary neointimal formation. Circulation (1994) 89:2768-2779.
124. SINGER JS, MHOYAN A, FISHBEIN MC et al.: Allochimeric class I MHC molecules prevent chronic rejection and attenuate alloantibody responses. Transplantation (2001) 72:1408-1416.
125. YAMAGUCHI A, WOODBURN KW, HAYASE M et al.: Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental coronary artery disease. Transplantation (2001) 71:1542-1548.
126. HILLEBRANDS JL, RAUE HP, KLATTER FA et al.: Intrathymic immune modulation prevents acute rejection but not the development of graft atherosclerosis (chronic rejection). Transplantation (2001) 71:914-924.
127. UMEDA Y, IWATA H, YOSHIKAWA S et al.: Gene gun-mediated CTLA4Ig-gene transfer for modification of allogeneic cardiac grafts. Transplant Proc. (2002) 34:2622-2623.
128. ORLOFF MS, DEMARA, COPPAGE ML et al.: Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation (1995) 59:282-288.
129. SHIRWAN H, WANG HK, BARWARI L et al.: Pre-transplant injection of allograft recipients with donor blood or lymphocytes permits allograft tolerance without the presence of persistent donor microchimerism. Transplantation (1996) 61:1382-1386.
130. KAWAI T, COSIMI AB, WEE SL et al.: Effect of hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation (2002) 73:1757-1764.
131. MINAMI E, LAFLAMME MA, SAFFITZ JE et al.: Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart. Circulation (2005) 112:2951-2958.
132. SIMPER D, WANG S, DEB A et al.: Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculaopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation (2003) 108:143-149.
133. MUSCI M, LOEBE M, WELLNHOFER E et al.: Coronary angioplasty, bypass surgery and retransplantation in cardiac transplant patients with graft coronary disease. Thorac. Cartliovasc. Surg. (1998) 46:268-274.
134. HALLE AA, DISCIASCIO G, MASSIN EK et al.: Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J. Am. Coll. Cardiol. (1995) 26:120-128.
135. MILLER LW, DONOHUE TJ, WOLFORD TA: The surgical management of allograft coronary disease: a paradigm shift. Semin. Thorac. Cardiovasc. Surg. (1996) 8:133-138.
136. ALEKSIC I, PIOTROWSKY JA, KAMLER M, HEROLD U, JAKOB HG: Minimally invasive direct coronary artery bypass in a cardiac transplant recipient with ailograft vasculopathy. Ann. Thorac. Surg. (2004) 77:1433-1434.
137. PARRY A, ROBERTS M, PARAMESHWAR J et al.: The management of post-cardiac transplantation coronary artery disease. Eur. J. Cardiothorac. Surg. (1996) 10:528-532.
138. WONG PM, PIAMSOMBOOM C, MATHUR et al.: Efficacy of coronary stenting in the management of cardiac allograft vasculopathy. Am. J. Cardiol. (1998) 82:239-240.
139. MARELLI M, RÁBAGO G, CALABUIG J et al.: Midterm results of percutaneous transluminal coronary angioplasty in graft coronary artery disease in cardiac transplant patients. Transplant Proc. (1999) 31:2539-25341.
140. BENZA RL, ZOGHBI GJ, TALLAJ J et al.: Palliation of allograft vasculopathy with transluminal angioplasty - a decade of experience. J. Am. Coll. Cardiol. (2004) 43:1973-1981.
141. SIMPSON L, LEE EK, HOTT BJ, VEGA DJ, BOOK WM: Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J. Heart Lung Transplant. (2005) 24:1211-1217
142. WESTON MW, SPOTO E, SOMMERS E et al.: Stenting unprotected left main coronary artery stenosis in heart transplant patients - the good, bad, and the ugly. J. Heart Lung Transplant. (2001) 20:1228-1232.
143. CHAN AW, CARERE RG, KHATRI S et al.: Unprotected left main coronary artery stenting for cardiac allograft vasculopathy. J. Heart Lung Transplant. (2001) 20:776-780.
144. DE GEVIGNEY G, RORIZ R, MACFADDEN E et al.: Should we still perform angioplasty and stenting of an unprotected left main coronary artery stenosis in heart transplant patients? Two new cases and a review of the literature. J. Heart Lung Transplant. (2001) 20:1217-1219.
145. KOYANAGI T, KYO S, OUCHI H et al.: Combined coronary intervention in heart-transplant patient with rapidly accelerated cardiac allograft vasculopathy. Jpn J. Thorac. Cardiovasc. Surg. (2001) 49:117-121.
146. ARANDA JM, PAULY DF, KERENSKY RA et al.: Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy: one center's experience. J. Heart Lung Transplant. (2002) 21:860-866.
147. SOUSA JE, COSTA MA, ABIZAID AC et al.: Sustained supression of neointimal proliferation by sirolimus-eluting stents: one year angiographic and intravascular ultrasound follow-up. Circulation (2001) 104:2007-2011
148. KLAUSS V, STEMPFLE H-U, THEISEN K et al.: Vascular brachytheraphy for treatment of cardiac allograft vasculopathy. J. Heart Lung Transplant. (2001) 20:792-794.
149. AQEL R, GUPTA R, TALLAJ JA, ZOGHBI GJ: Re-stenosis of a sirolimus-coated stint in a heart transplant recipient with allograft vasculopathy. J. Heart Lung Transplant. (2005) 24(9):1444.
150. JOHN R, CHEN JM, WEINBERG A et al.: Long-term survival after cardiac retransplantation: a twenty-year single center experience. J. Thorac. Cardiovasc. Surg. (1999) 117:543-555.
151. MANCINI D, PINNEY S, BURKHOFF D et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation (2003) 108:48-53.
152. SEGOVIA J, ALONSO-PULPÓN L, ORTIZ P et al.: Rapastat: evaluation of the role of oral sirolimus in the treatment of established graft vessel disease. A prospective, randomized intravascular ultrasound study. J. Heart Lung Transplant. (2004) 23(Suppl.):S51-S52.
153. ORTIZ P, SEGOVIA J, ALONSO-PULPÓN L et al.: Valoración mediante ecografia intracoronaria del efecto del sirolimus en la enfermedad vascular del injerto cardíaco de grado avanzado. Rev. Esp. Cardiol. (2004) 57(Suppl.):42.
154. MEHRA MR, KOBASHIGAWA JA: Advances in heart and lung transplantation 2004: report from the 24th International Society for Heart and Lung Transplantation Annual Meeting, San Francisco, April 21-24, 2004. J. Heart Lung Transplant. (2004) 23:925.